{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:11:21Z","timestamp":1794028281555,"version":"4.8.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100015132","name":"Foundation for Women\u2019s Wellness","doi-asserted-by":"publisher","award":["2024A003001"],"award-info":[{"award-number":["2024A003001"]}],"id":[{"id":"10.13039\/100015132","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Somatostatin receptor ligands (SRLs) are the mainstay of pharmacotherapy for acromegaly. Patients report symptoms toward the end of the injection cycle. However, the correlation between insulin-like growth factor-I (IGF-I) and patient-reported outcomes (PROMs) has not been evaluated in this context.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine IGF-I, PROMs, and SRL concentration variability in patients with acromegaly receiving long-acting SRLs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Quality of life surveys, early and late phase (weeks 1 and 4 after SRL injection) biochemical markers, and SRL concentrations were obtained in 20 patients receiving monthly SRLs during 2 injection cycles. All IGF-I levels were measured using both mass spectrometry (LC\u2013MS) and an immunoassay (IDS-iSYS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>IGF-I concentrations were higher during late vs early phase of cycle 2 using LC\u2013MS (179.5 \u00b1 85.6\u2005ng\/mL vs 154.8 \u00b1 80.2\u2005ng\/mL, P = .045) and IDS-iSYS (201.2 \u00b1 86.3\u2005ng\/mL vs 165.5 \u00b1 75.8\u2005ng\/mL, P = .023) assays. In cycle 1, PASQ scores worsened in week 4 (18.10 \u00b1 11.96) compared to week 2 (15.53 \u00b1 9.94; P = .011) and week 3 (15.00 \u00b1 12.49; P = .021). SRL concentrations were lower during late phase (3563 \u00b1 1444\u2005pg\/mL vs 2588 \u00b1 1085\u2005pg\/mL; P = .008). Change in (\u0394)SRL negatively correlated with \u0394IGF-I IDS-iSYS (r = \u22120.385, P = .047). \u0394ACROQoL physical significantly correlated with \u0394IGF-I. \u0394soluble alpha-klotho (s\u03b1KL) correlated with \u0394PASQ score (r = 0.337, P = .034) and swelling (r = 0.335, P = .035).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>IGF-I concentrations increased according to time since SRL injection. Patient-reported outcomes fluctuated, correlating with IGF-I and s\u03b1KL changes. Measuring IGF-I at the end of the injection cycle is advisable. Decreases in SRL concentration suggest phase-based differences in IGF-I concentrations. These findings inform personalized approaches to acromegaly, with titration of therapy based on individual IGF-I and\/or PROMs fluctuation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ejendo\/lvaf200","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:00:40Z","timestamp":1758801640000},"page":"464-473","source":"Crossref","is-referenced-by-count":13,"title":["Insulin-like growth factor-I and symptoms of acromegaly according to time since somatostatin receptor ligand injection"],"prefix":"10.1093","volume":"193","author":[{"given":"Ilan","family":"Remba-Shapiro","sequence":"first","affiliation":[{"name":"Neuroendocrine Unit, Massachusetts General Hospital, Harvard Medical School , Boston, MA 02114 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fania R O L","family":"Schweizer","sequence":"additional","affiliation":[{"name":"Endocrine Laboratory, Medizinische Klinik und Poliklinik IV, LMU Klinikum , Munich 80336 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Moscona-Nissan","sequence":"additional","affiliation":[{"name":"Neuroendocrine Unit, Massachusetts General Hospital, Harvard Medical School , Boston, MA 02114 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen J P","family":"Liebert","sequence":"additional","affiliation":[{"name":"Neuroendocrine Unit, Massachusetts General Hospital, Harvard Medical School , Boston, MA 02114 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela S","family":"Jones","sequence":"additional","affiliation":[{"name":"Departement of Neurosurgery, Massachusetts General Hospital, Harvard Medical School , Boston, MA 02114 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8667-0296","authenticated-orcid":false,"given":"Katharina","family":"Schilbach","sequence":"additional","affiliation":[{"name":"Endocrine Laboratory, Medizinische Klinik und Poliklinik IV, LMU Klinikum , Munich 80336 ,","place":["Germany"]},{"name":"Deggendorf Institute of Technology , Deggendorf 94469 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Naredo Rojas","sequence":"additional","affiliation":[{"name":"Neuroendocrine Unit, Massachusetts General Hospital, Harvard Medical School , Boston, MA 02114 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Adams","sequence":"additional","affiliation":[{"name":"Neuroendocrine Unit, Massachusetts General Hospital, Harvard Medical School , Boston, MA 02114 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky O","family":"Cheng","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Brown University , Providence, RI 02915 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A","family":"Tritos","sequence":"additional","affiliation":[{"name":"Neuroendocrine Unit, Massachusetts General Hospital, Harvard Medical School , Boston, MA 02114 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4681-6668","authenticated-orcid":false,"given":"Martin","family":"Bidlingmaier","sequence":"additional","affiliation":[{"name":"Endocrine Laboratory, Medizinische Klinik und Poliklinik IV, LMU Klinikum , Munich 80336 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5708-5231","authenticated-orcid":false,"given":"Lisa B","family":"Nachtigall","sequence":"additional","affiliation":[{"name":"Neuroendocrine Unit, Massachusetts General Hospital, Harvard Medical School , Boston, MA 02114 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"issue":"11","key":"2025111719113438000_lvaf200-B1","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/S2213-8587(22)00244-3","article-title":"Acromegaly: pathogenesis, diagnosis, and management","volume":"10","author":"Fleseriu","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2025111719113438000_lvaf200-B2","doi-asserted-by":"publisher","first-page":"101309","DOI":"10.1016\/j.beem.2019.101309","article-title":"The burden of disease for pituitary patients","volume":"33","author":"Biermasz","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"4","key":"2025111719113438000_lvaf200-B3","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","article-title":"Multidisciplinary management of acromegaly: a consensus","volume":"21","author":"Giustina","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"issue":"4","key":"2025111719113438000_lvaf200-B4","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s11102-024-01397-w","article-title":"Standards of care for medical management of acromegaly in pituitary tumor centers of excellence (PTCOE)","volume":"27","author":"Giustina","year":"2024","journal-title":"Pituitary"},{"issue":"3","key":"2025111719113438000_lvaf200-B5","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s11102-014-0570-0","article-title":"Octreotide LAR treatment of acromegaly in \u201creal life\u201d: long-term outcome at a tertiary care center","volume":"18","author":"Espinosa-de-los-Monteros","year":"2015","journal-title":"Pituitary"},{"issue":"3","key":"2025111719113438000_lvaf200-B6","doi-asserted-by":"publisher","first-page":"e532","DOI":"10.1210\/clinem\/dgz187","article-title":"Biochemical control in acromegaly with multimodality therapies: outcomes from a pituitary center and changes over time","volume":"105","author":"Ghajar","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2025111719113438000_lvaf200-B7","doi-asserted-by":"publisher","first-page":"e3785","DOI":"10.1210\/clinem\/dgaa526","article-title":"Maintenance of acromegaly control in patients switching from injectable somatostatin receptor ligands to oral octreotide","volume":"105","author":"Samson","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025111719113438000_lvaf200-B8","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1210\/jc.2013-3318","article-title":"Tumor shrinkage with lanreotide Autogel 120\u2005mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial","volume":"99","author":"Caron","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025111719113438000_lvaf200-B9","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1210\/jc.2013-3757","article-title":"Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis","volume":"99","author":"Carmichael","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025111719113438000_lvaf200-B10","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s11102-019-01013-2","article-title":"Observed discordance between outcomes reported by acromegaly patients and their treating endocrinology medical provider","volume":"23","author":"Geer","year":"2020","journal-title":"Pituitary"},{"issue":"3","key":"2025111719113438000_lvaf200-B11","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1530\/EJE-15-1042","article-title":"Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly","volume":"174","author":"Strasburger","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2025111719113438000_lvaf200-B12","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1530\/EJE-21-1071","article-title":"Virtual education programming for patients with acromegaly: a pilot study","volume":"186","author":"Geer","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"2025111719113438000_lvaf200-B13","doi-asserted-by":"publisher","first-page":"e3644","DOI":"10.1210\/clinem\/dgac385","article-title":"IGF-I variability over repeated measures in patients with acromegaly under long-acting somatostatin receptor ligands","volume":"107","author":"Maione","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2025111719113438000_lvaf200-B14","doi-asserted-by":"publisher","first-page":"e2887","DOI":"10.1210\/clinem\/dgab257","article-title":"Soluble alpha klotho in acromegaly: comparison with traditional markers of disease activity","volume":"106","author":"Schweizer","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025111719113438000_lvaf200-B15","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1093\/ejendo\/lvaf093","article-title":"Soluble alpha klotho\u2014impact of biological variables and reference intervals for adults","volume":"192","author":"Schweizer","year":"2025","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2025111719113438000_lvaf200-B16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11102-017-0849-z","article-title":"Discordance between mass spectrometry and immunometric IGF-1 assay in pituitary disease: a prospective study","volume":"21","author":"Bonert","year":"2018","journal-title":"Pituitary"},{"issue":"23","key":"2025111719113438000_lvaf200-B17","doi-asserted-by":"publisher","first-page":"9005","DOI":"10.1021\/ac201800g","article-title":"Narrow mass extraction of time-of-flight data for quantitative analysis of proteins: determination of insulin-like growth factor-1","volume":"83","author":"Bystrom","year":"2011","journal-title":"Anal Chem"},{"issue":"5","key":"2025111719113438000_lvaf200-B18","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1210\/jc.2013-3059","article-title":"Reference intervals for insulin-like growth factor-1 (igf-i) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations","volume":"99","author":"Bidlingmaier","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2025111719113438000_lvaf200-B19","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1373\/clinchem.2012.188128","article-title":"Automated 22-kD growth hormone-specific assay without interference from Pegvisomant","volume":"58","author":"Manolopoulou","year":"2012","journal-title":"Clin Chem"},{"issue":"5","key":"2025111719113438000_lvaf200-B20","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1210\/jc.2013-3060","article-title":"Age- and sex-specific reference intervals across life span for insulin-like growth factor binding protein 3 (IGFBP-3) and the IGF-I to IGFBP-3 ratio measured by new automated chemiluminescence assays","volume":"99","author":"Friedrich","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025111719113438000_lvaf200-B21","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1530\/eje.1.02214","article-title":"Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQoL: a 6-month prospective study","volume":"155","author":"Webb","year":"2006","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"2025111719113438000_lvaf200-B22","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1210\/jc.2008-0669","article-title":"Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant","volume":"93","author":"Neggers","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025111719113438000_lvaf200-B23","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1365-2265.2005.02307.x","article-title":"Assessment of quality of life in patients with uncontrolled vs. Controlled acromegaly using the acromegaly quality of life questionnaire (AcroQoL)","volume":"63","author":"Trepp","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2025111719113438000_lvaf200-B24","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/j.1365-2265.2007.02891.x","article-title":"Treatment of acromegaly improves quality of life, measured by AcroQol","volume":"67","author":"Paisley","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2025111719113438000_lvaf200-B25","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1210\/clinem\/dgab874","article-title":"State of the art of patient-reported outcomes in acromegaly or GH deficiency: a systematic review and meta-analysis","volume":"107","author":"van der Meulen","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025111719113438000_lvaf200-B26","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1210\/clinem\/dgaa868","article-title":"Improvement in symptoms and health-related quality of life in acromegaly patients: a systematic review and meta-analysis","volume":"106","author":"Broersen","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025111719113438000_lvaf200-B27","first-page":"190","article-title":"Least significant changes and monitoring time intervals for high-resolution pQCT-derived bone outcomes in postmenopausal women","volume":"15","author":"Kawalilak","year":"2015","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"1","key":"2025111719113438000_lvaf200-B28","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/0026-0495(94)90153-8","article-title":"Octreotide: a long-acting inhibitor of endogenous hormone secretion for human metabolic investigations","volume":"43","author":"Krentz","year":"1994","journal-title":"Metabolism"},{"key":"2025111719113438000_lvaf200-B29","doi-asserted-by":"publisher","first-page":"111038","DOI":"10.1016\/j.mce.2020.111038","article-title":"Effect of growth hormone on insulin signaling","volume":"518","author":"Sharma","year":"2020","journal-title":"Mol Cell Endocrinol"},{"issue":"8","key":"2025111719113438000_lvaf200-B30","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1210\/jc.2011-0273","article-title":"Growth hormone (GH)-induced insulin resistance is rapidly reversible: an experimental study in GH-deficient adults","volume":"96","author":"Krusenstjerna-Hafstr\u00f8m","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"8 Suppl 1","key":"2025111719113438000_lvaf200-B31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0026-0495(96)90075-X","article-title":"Sandostatin LAR (microencapsulated octreotide acetate) in acromegaly: pharmacokinetic and pharmacodynamic relationships","volume":"45","author":"Grass","year":"1996","journal-title":"Metabolism"},{"key":"2025111719113438000_lvaf200-B32","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/0026-0495(95)90306-2","article-title":"Sandostatin LAR\u00ae: pharmacokinetics, pharmacodynamics, efficacy, and tolerability in acromegalic patients","volume":"44","author":"Lancranjan","year":"1995","journal-title":"Metabolism"},{"issue":"10","key":"2025111719113438000_lvaf200-B33","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.metabol.2005.04.014","article-title":"Pharmacokinetics and population pharmacodynamic analysis of lanreotide autogel","volume":"54","author":"Cendros","year":"2005","journal-title":"Metabolism"},{"issue":"12","key":"2025111719113438000_lvaf200-B34","doi-asserted-by":"publisher","first-page":"3601","DOI":"10.1210\/jcem.80.12.8530606","article-title":"Sandostatin LAR in acromegalic patients: a dose-range study","volume":"80","author":"Fl\u00f8gstad","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025111719113438000_lvaf200-B35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1210\/jcem.82.1.3572","article-title":"Sandostatin LAR in acromegalic patients: long-term treatment","volume":"82","author":"Fl\u00f8gstad","year":"1997","journal-title":"J Clin Endocrinol Metab"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/advance-article-pdf\/doi\/10.1093\/ejendo\/lvaf200\/64399194\/lvaf200.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/193\/4\/464\/64399194\/lvaf200.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/193\/4\/464\/64399194\/lvaf200.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:11:41Z","timestamp":1763424701000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/193\/4\/464\/8264412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,9,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvaf200","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,9,26]]}}}